

Cobimetinib Development Program

As of April 10, 2019; for a full list of ongoing studies, please visit www.clinicaltrials.gov

PHASE 3 DEVELOPMENT ACTIVITIES*

Indication / Disease State	Combination Regimen	Status Update
Metastatic or Unresectable Locally Advanced Melanoma		
BRAF V600 mutation-positive	+ vemurafenib	Approved in U.S., EU and other territories (coBRIM trial)
First-line BRAF V600 mutation-positive	+ atezolizumab + vemurafenib	IMspire150 trial: fully enrolled, with data anticipated in 2019‡
First-line BRAF wild-type	+ atezolizumab	IMspire170 trial: fully enrolled, with data anticipated in 2019‡

SELECT ADDITIONAL DEVELOPMENT ACTIVITIES

Indication / Disease State	Combination Regimen	Status Update
First-line triple-negative breast cancer	+ taxanes +/- atezolizumab	Phase 2 trial (COLET trial)
Metastatic pancreatic ductal adenocarcinoma	+ atezolizumab	Phase 1b/2 trial (one arm of an umbrella study)
Metastatic colorectal cancer	+ atezolizumab + bevacizumab	Phase 1b trial

Cobimetinib is also being evaluated in additional clinical trials of various combination regimens, including:

- With vemurafenib, and with vemurafenib + atezolizumab, trials in additional melanoma patient populations and settings
- With atezolizumab, phase 2 studies in renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, and hormone receptor positive, HER2 negative breast cancer, and phase 1/2 studies in melanoma and non-small cell lung cancer
- With venetoclax, phase 1/2 studies in relapsed or refractory acute myeloid leukemia and multiple myeloma



* Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech's investigator sponsored trial program. The phase 3 trials indicated in the above table are all sponsored by Genentech.

‡ As communicated on Roche's full year 2018 financial results presentation, January 31, 2019.